Cafe des Sciences de Boston

Pour cette 24ème édition du Café des Sciences de Boston, événement mensuel regroupant la communauté scientifique et technologique francophone ou francophile de Nouvelle Angleterre, nous avons la joie d’accueillir une delegation de 10 societe du pole de competitivite SYSTEM@TIC.

Deux d’entre elles, MLState et Kayentis, vous presenteront leurs technologies tout-a-fait innovantes et projet de developpement aux Etats-Unis.

Pour cette 23ème édition du Café des Sciences de Boston, événement mensuel regroupant la communauté scientifique et technologique francophone ou francophile de Nouvelle Angleterre, nous avons l’honneur de vous accueillir à la Résidence de France pour échanger avec le prof. Jean Pierre Bourguignon, directeur de l‘Institut des Hautes Etudes Scientifiques.

A partir de son expérience de mathématicien, d’enseignant et de directeur d’un institut de recherche indépendant (fondation privée), le professeur Bourguignon voudrait vous faire partager son inquiétude et sa frustration devant les risques induits par l’évolution de l’organisation de la recherche dans quelques pays. Son exposé comporte deux parties apparemment disjointes : la première fait en quelque sorte le point sur la façon dont le développement des mathématiques se nourrit (son coeur, leurs applications et leurs interfaces) ; la seconde analyse les effets de la nouvelle organisation de la recherche dans les grands pays producteurs de connaissances et les conséquences sur le développement des sciences mathématiques.

La présentation sera suivie d’un pot de l’amitié, offert par le Consul Général de France, M. Christophe Guilhou.

Le nombre de places est limité, veuillez vous inscrire au plus vite, premier arrivé, premier servi !

Isaac De La Penã, the Head of Internet Strategic Initiatives at Nokia, is an expert in innovation management, corporate ventures and mobile strategy. Originally from Spain, he has an international experience heading multicultural teams on complex projects. His multidisciplinary profile ensures adaptability and top performance in a fast changing business environment. As the head of internet strategic initiatives for Nokia, he is responsible for the strategic transformation of Nokia into an Internet-savvy company, developing the projects, capabilities and resources necessary for the company to compete in a converged mobile 2.0 market. Isaac is also a visiting Scientist at the MIT Media Labs, participating in joint research programs with MIT faculty and students, fostering the creation of an environment that harnesses the power of open innovation at Nokia. He owns two bachelor’s degrees in economics and philosophy and an MBA from the MIT Sloan School of management. He also had strategy training classes at Harvard University with Prof. Clayton Christensen.

Maxime Moulard is CSO for BioCytex, a company that develops quantitative flow cytometry application kits. BioCytex is performing R&D and clinical investigations for major worldwide pharmaceutical companies. Biocytex is currently involved in developing diagnostic tools that can be used in a large spectrum of diseases including cancer, inflammatory diseases and hemostasis. Maxime has been involved in establishing and managing major corporate collaborations and partnerships (Eli Lilly, Sanofi-Aventis) as well as numerous academic and Institutional collaborations.
Prior to joining BioCytex in 2001, he was Visiting Scientist at The Scripps Research Institute (TSRI), in La Jolla, from 1998 to 2000. His scientific interests led him to develop new methods to generate and characterize human monoclonal antibodies using phage-display technologies. He received his Ph.D. in Biochemistry from the University Pierre & Marie Curie (Paris, France) and completed his post-doctoral training at the Institute für Virology in Marburg, Germany. He has published over 30 original manuscripts, book chapters, patents and reviews and has been a regular contributor of original research to the field of protein interaction and signaling mechanisms.

Valérie Philippon, Director of Publication Strategy and Management at Vertex

Valérie Philippon is the Director of Publication Strategy and Management at Vertex Pharmaceuticals, a company based in Cambridge, MA that is seeking to transform the way serous diseases are treated. She is responsible for the development and execution of Publication Strategy for Vertex HCV franchise. Valérie has over 15 years of experience in Research, Development, Program & Portfolio Management, Medical Writing and Publication Planning. She received her Ph.D. in Microbiology from the University of Paris, France where she studied the molecular pathogenesis of retroviruses. She continued in research doing a post-doctoral fellowship at Harvard School of Public Health under the direction of Dr Max Essex and studying the role of Vpr and Vpx proteins in HIV and SIV pathogenesis. Following the completion of her fellowship she accepted a scientist position at Therion Biologics where, as a scientist and program manager, she participated in the discovery and development of cancer immunotherapies and was responsible for the company HIV vaccine development. She then joined Idenix Pharmaceuticals as a Medical Writer where her responsibilities extended from helping clinicians and scientists to write abstracts, conference presentations and manuscripts to coordinate publication planning for the company’s HBV, HCV and HIV drug candidates.

Marc Rioult, MIT Technology Licensing Officer

Le MIT est une universite tres active en development et en commercialisation de technologie: environs 1,000 enseignants et chefs de labos, 500 nouvelles inventions par an, 350 demandes de brevets, 120 licenses ou transactions similaires, 20-25 spin-offs, et $80-90 millions de revenus generes par une organisation de 30 personnes seulement. Parmi plusieurs facteurs contribuants, la recherche scientifique au MIT qui invite souvent les applications pratiques en plus de la recherche fondamentale, et un climat d’entrepreneuriat unique et bien etabli parmi tous les elements du MIT -etudiants, enseignants et chefs de labos, administration, etc.- contribuent a cette situation. Nous discuterons du travail du Technology Licensing Office du MIT en general, ainsi que de quelques cas illustrant certains aspects de la commercialisation de technologie creee au sein d’une universite aux U.S.

A propos de Marc Rioult

Experience: -MIT – Technology Licensing Office, Technology Licensing Officer, since 2008: technology licensing, intellectual property portfolio management, facilitation of start-up creation; -Yet2.com Inc., Director Deal Facilitation, 2004-2007: licensing deal, consulting projects both in technology commercialization and acquisition, sales of consulting services and client acquisition, management of client accounts in the US and Europe; -Foresight Science & Technology, Inc., VP Consulting, 2001-2004: managed private client accounts and Federal accounts for EPA, ONR, and other Federal agencies; term sheets, market evaluations, technology assessments, coaching on business plans, etc. -AutoQuant Imaging, Inc., Director of Operations, 2000-2001: lead business development, marketing and sales, customer service, and IP development; P&L responsibility for all commercial activities. -Brown University (neuroscience) 1995-2000; Yale University (neuroscience, parasitology) 1993-1995; ETH Zurich/University of Berne (neuroscience) 1986-1992, PhD thesis. Consulted for various companies ranging from startups to Fortune 500, and for private, government, and universities laboratories in the US and Europe. Education: Executive MBA, Boston University, Boston, 2000; PhD Neuroscience, ETH Zurich, 1991; MS Life sciences/Biomedical engineering, ETH Zurich, 1984.

HORAIRE HABITUEL: 6pm-8pm
Lieu: Hubtech21, One Broadway 11th floor – Cambridge 02142
T: Kendall Square
please RSVP ou sur Facebook

Le Président Aoun nous présentera le modèle Northeastern, le renforcement de ses collaborations internationales ainsi que les liens très forts tissés entre l’université et le monde de l’entreprise. Northeastern University a été élue en 2008, meilleure université américaine pour le placement professionnel de ses étudiants par la Princeton Review.

Joseph E. Aoun, an internationally known scholar in linguistics, is the seventh president of Northeastern University-a preeminent global, experiential, research university. Since his presidency began in August 2006, he has charted an ambitious and distinctive course to advance Northeastern. At the heart of his vision is a commitment to strengthen the University’s leadership position in experiential and cooperative education; create global programs with an urban perspective; foster a research environment where faculty uncover solutions to real-world problems; and build innovative partnerships so that Northeastern can better serve its students, its city, the nation, and the world.

President Aoun serves on the boards of directors of the American Council on Education, Artists for Humanity, the Boston Private Industry Council, Boston World Partnerships, Jobs for Mass, and the New England Council.

He is a member of the Executive Committee of the Greater Boston Chamber of Commerce, a member of the Massachusetts Business Roundtable and Massachusetts Math & Science Initiative, and serves on the Leadership Council for the Massachusetts Life Sciences Collaborative and as cochair of the City to City Boston initiative.

President Aoun received his PhD in linguistics and philosophy from the Massachusetts Institute of Technology in 1981; his Diploma of Advanced Studies in General and Theoretical Linguistics from the University of Paris (France) VIII in 1977; and his Masters in Oriental Languages and Literature from Saint Joseph University (Beirut, Lebanon) in 1975. In 2006 he was presented with the Chevalier de L’ordre des Palmes Academiques from the French Government, and in May of 2007 Hebrew Union College – Jewish Institute of Religion presented him the degree of Doctor of Humane Letters, honoris causa. President Aoun has published seven books and written more than 40 articles.

Frederic Chereau
President & Chief Executive Officer of Pervasis Therapeutics

Mr. Chereau assumed the role of President and Chief Executive Officer at Pervasis Therapeutics in September 2008. Prior to Pervasis, Mr. Chereau was the Vice President and General Manager of Genzyme Cardiovascular, a business unit of Genzyme Corporation. As VP and General Manager, Mr. Chereau led teams focusing on commercialization of a hypercholesterolemia product (Cholestagel), development of a late clinical stage gene therapy program in Peripheral Arterial Disease, and a broad range of business development activities. In addition, Mr. Chereau served as the Chief Operating Officer of MG Biotherapeutics LLC, a Genzyme and Medtronic joint-venture formed to develop cellular therapies for cardiac repair.
From 1999 to 2005, Mr. Chereau held various marketing and business development positions within Genzyme with growing responsibilities in France and Europe. During this time, he was appointed as CEO of Myosix SA, a cell therapy company based in France with an ongoing close relationship with Genzyme Cardiovascular’s cell therapy programs. He relocated to the United States in 2005 and was promoted to Vice President and General Manager of Cardiovascular Business Unit in November 2006.
Prior to Genzyme, Mr. Chereau started his career in sales and product management for a French medical device retail company in the hemodialysis and blood transfusion field.
Mr. Chereau holds a B.S. in Physics from Paris University, completed graduate studies at the La Rochelle Business School and received an M.B.A. from INSEAD
HORAIRE HABITUEL: 6pm-8pm
Lieu: Hubtech21, One Broadway 11th floor – Cambridge 02142
T: Kendall Square
please RSVP ou sur Facebook

La ville de Grenoble, avec ses 2 grands pôles de recherche et d’éducation que sont le polygone scientifique et le campus universitaire, se place aujourd’hui au rang de 2ème métropole des sciences et technologies en France.
Le polygone scientifique à Grenoble est la réussite d’un modèle collaboratif inédit entre recherche, enseignement et industrie, renforcé par le soutien actif des collectivités territoriales. Véritable creuset de l’innovation, le polygone scientifique est le principal moteur de la croissance économique de l’écosystème grenoblois.
Forts de l’expérience Minatec, les organismes de recherche et d’enseignement du polygone portent, depuis 2 ans, le projet GIANT, dont l’objectif est de consolider les acteurs du polygone autour de 3 enjeux sociétaux fondamentaux que sont l’information, la santé et l’énergie et de faire de ce site un des plus grands centres technologiques et scientifiques mondiaux.
GIANT, c’est 8000 chercheurs et ingénieurs, 10 000 étudiants, 5 000 publications et près de 440 brevets par an (3ème déposant français). C’est également un site de 220 hectares, 400 000m² de bâtiments dédiés à la recherche et l’éducation et 120 000m² de nouveaux bâtiments qui seront construits dans les 10 prochaines années. Et c’est surtout un ensemble de laboratoires et d’instituts de recherche salué pour leur excellence académique et technologique, renforcés par la présence de grands instruments européens (ESRF, ILL).
Le projet GIANT est également un des deux piliers de la future Grenoble Université de l’Innovation, en association avec le campus universitaire de Saint Martin d’Hères. Grenoble Université de l’Innovation, la réponse à l’appel à projet Opération Campus initié par Valérie Pécresse en 2008, a été salué pour son ambition et son effet structurant.Intervenants :
Geneviève Fioraso, Député, 1ère Vice-Présidente de Grenoble Alpes Métropole et Présidente de Minatec Entreprise
Erwann Binet, Vice-Président chargé du développement économique et de la recherche au Conseil Général de l’Isère
Stéphane Siebert, Chef de projet GIANT et Grenoble Université de l’Innovation pour le CEA

Head, Clinical Transplantation Immunology Laboratory
Director, Transplant Center Sample Repository
Senior Investigator, Bone Marrow Transplantation Section
Assistant Immunologist, Massachusetts General Hospital
Assistant Professor of Surgery, Harvard Medical School  Emmanuel.Zorn@tbrc.mgh.harvard.eduDr. Zorn received his Ph.D. in tumor immunology from Paris University in 1999. He then joined Dana-Farber Cancer Institute to study graft versus leukemia and graft versus host disease following allogeneic hematopoietic stem cell transplantation. He was promoted to Instructor at Harvard Medical School in 2002. Dr. Zorn moved to the Transplantation Biology Research Center at Massachusetts General Hospital in 2006 where he is now a senior investigator.    

Link to Dr. Zorn’s Publications